JP6126204B2 - プロスタグランジンを主成分とした気管支拡張剤 - Google Patents
プロスタグランジンを主成分とした気管支拡張剤 Download PDFInfo
- Publication number
- JP6126204B2 JP6126204B2 JP2015508895A JP2015508895A JP6126204B2 JP 6126204 B2 JP6126204 B2 JP 6126204B2 JP 2015508895 A JP2015508895 A JP 2015508895A JP 2015508895 A JP2015508895 A JP 2015508895A JP 6126204 B2 JP6126204 B2 JP 6126204B2
- Authority
- JP
- Japan
- Prior art keywords
- nitroprostone
- keto
- dihydroxy
- inhalation
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940124630 bronchodilator Drugs 0.000 title claims description 11
- 150000003180 prostaglandins Chemical class 0.000 title description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 title description 2
- 239000003814 drug Substances 0.000 claims description 15
- 208000006673 asthma Diseases 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 230000000414 obstructive effect Effects 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 208000023504 respiratory system disease Diseases 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
- 239000000006 Nitroglycerin Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960001123 epoprostenol Drugs 0.000 claims 1
- 229960003711 glyceryl trinitrate Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 229960002986 dinoprostone Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 6
- 208000014181 Bronchial disease Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 229940125389 long-acting beta agonist Drugs 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- ASIGVDLTBLZXNC-UHFFFAOYSA-N 1,3-dinitroglycerol Chemical compound [O-][N+](=O)OCC(O)CO[N+]([O-])=O ASIGVDLTBLZXNC-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- WXAXNYYAYJKARR-UHFFFAOYSA-N benzene;2-(1,4-dioxan-2-yl)acetic acid Chemical compound C1=CC=CC=C1.OC(=O)CC1COCCO1 WXAXNYYAYJKARR-UHFFFAOYSA-N 0.000 description 1
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LSLYOANBFKQKPT-UHFFFAOYSA-N fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003915 liquefied petroleum gas Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- SGMBTYBNUOWYOV-CXZSOYKBSA-N nitroproston Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(=O)OC(CO[N+]([O-])=O)CO[N+]([O-])=O SGMBTYBNUOWYOV-CXZSOYKBSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229960000665 norflurane Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012116226 | 2012-04-24 | ||
| RU2012116226/15A RU2500397C1 (ru) | 2012-04-24 | 2012-04-24 | Бронхолитическое средство на основе простагландина |
| PCT/RU2013/000163 WO2013162416A1 (ru) | 2012-04-24 | 2013-03-01 | Бронхолитическое средство на основе простагландина |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506359A JP2016506359A (ja) | 2016-03-03 |
| JP2016506359A5 JP2016506359A5 (enExample) | 2016-05-19 |
| JP6126204B2 true JP6126204B2 (ja) | 2017-05-10 |
Family
ID=49446371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015508895A Expired - Fee Related JP6126204B2 (ja) | 2012-04-24 | 2013-03-01 | プロスタグランジンを主成分とした気管支拡張剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9408820B2 (enExample) |
| EP (1) | EP2842554B1 (enExample) |
| JP (1) | JP6126204B2 (enExample) |
| CN (1) | CN104470510A (enExample) |
| AU (1) | AU2013253042B2 (enExample) |
| BR (1) | BR112014026610A2 (enExample) |
| CA (1) | CA2871601C (enExample) |
| EA (1) | EA027724B1 (enExample) |
| RU (1) | RU2500397C1 (enExample) |
| WO (1) | WO2013162416A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015359723A1 (en) * | 2014-12-09 | 2017-04-27 | Société des Produits Nestlé S.A. | Uses of bioactive lipids |
| RU2662099C1 (ru) * | 2017-10-16 | 2018-07-23 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Фармацевтические композиции для ингаляций, содержащие нитропростон |
| RU2695068C1 (ru) * | 2018-06-26 | 2019-07-19 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Средство для лечения хронических облитерирующих заболеваний периферических сосудов на основе простагландина |
| CN117924133A (zh) * | 2022-10-17 | 2024-04-26 | 广州楷石医药有限公司 | 一种前列地尔偶联一氧化氮供体药物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2067094C1 (ru) * | 1993-09-27 | 1996-09-27 | Владимир Виленович Безуглов | 1,3-динитроглицериновые эфиры полиненасыщенных жирных кислот, гидроксипроизводных полиненасыщенных жирных кислот и простагландинов и способы их получения |
| US5625083A (en) * | 1995-06-02 | 1997-04-29 | Bezuglov; Vladimir V. | Dinitroglycerol esters of unsaturated fatty acids and prostaglandins |
-
2012
- 2012-04-24 RU RU2012116226/15A patent/RU2500397C1/ru active
-
2013
- 2013-03-01 JP JP2015508895A patent/JP6126204B2/ja not_active Expired - Fee Related
- 2013-03-01 AU AU2013253042A patent/AU2013253042B2/en not_active Ceased
- 2013-03-01 CN CN201380022111.6A patent/CN104470510A/zh active Pending
- 2013-03-01 CA CA2871601A patent/CA2871601C/en active Active
- 2013-03-01 BR BR112014026610A patent/BR112014026610A2/pt not_active Application Discontinuation
- 2013-03-01 WO PCT/RU2013/000163 patent/WO2013162416A1/ru not_active Ceased
- 2013-03-01 EP EP13781656.7A patent/EP2842554B1/en not_active Not-in-force
- 2013-03-01 US US14/397,092 patent/US9408820B2/en active Active
- 2013-03-01 EA EA201401178A patent/EA027724B1/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EA201401178A1 (ru) | 2015-10-30 |
| BR112014026610A2 (pt) | 2017-07-18 |
| JP2016506359A (ja) | 2016-03-03 |
| US20150141505A1 (en) | 2015-05-21 |
| EP2842554A4 (en) | 2016-01-06 |
| US9408820B2 (en) | 2016-08-09 |
| CN104470510A (zh) | 2015-03-25 |
| EA027724B1 (ru) | 2017-08-31 |
| WO2013162416A1 (ru) | 2013-10-31 |
| CA2871601A1 (en) | 2013-10-31 |
| AU2013253042B2 (en) | 2017-08-31 |
| AU2013253042A1 (en) | 2014-12-11 |
| CA2871601C (en) | 2020-02-18 |
| RU2012116226A (ru) | 2013-10-27 |
| EP2842554A1 (en) | 2015-03-04 |
| EP2842554B1 (en) | 2018-10-24 |
| RU2500397C1 (ru) | 2013-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4021327B2 (ja) | Ｆｘｒに対する作用薬としてのステロイド | |
| JPH06505233A (ja) | 新規ステロイドエステル | |
| JPH04504726A (ja) | アナフィラキシーの遅反応性物質に対する拮抗薬としてのリポキシンａ↓４およびその誘導体の使用 | |
| JP6126204B2 (ja) | プロスタグランジンを主成分とした気管支拡張剤 | |
| KR20040032851A (ko) | Δ^8 테트라히드로카나비놀의 에어로졸 제형 | |
| TW200940070A (en) | C-21 thioethers as glucocorticoid receptor agonists | |
| US20240294453A1 (en) | Deuterated agonists and methods of use | |
| WO2004007521A2 (en) | Bile acid derivatives as agonists of the farnesoid x receptor | |
| JP2650756B2 (ja) | 皮膚および粘膜上皮の疾患の治療のための４‐キノリンカルボン酸誘導体 | |
| JP2006506363A (ja) | Ｓｈｉｐ１モデュレーター | |
| CN104513290A (zh) | 雷醇内酯衍生物及其应用 | |
| JP2016506359A5 (enExample) | ||
| Zhou et al. | A novel strategy for development of glucocorticoids through non-genomic mechanism | |
| WO2004026298A1 (en) | Derivatives of triptolide having high immunosuppressive effect and high water solubility, and uses thereof | |
| TWI242433B (en) | Inhaled combination and pharmaceutical composition comprising a selective PDE4 inhibitor and an adrenergic beta2 receptor agonist | |
| TWI463985B (zh) | 單離自金剛纂之化合物於癌症和／或血小板數量低下之治療用途 | |
| WO2019178331A1 (en) | 3",5"-dialkoxybenzoyl-3'-amino-3'-deoxyadenosine-5'-triphosphates and pharmaceutical uses thereof | |
| JPS5982399A (ja) | 細胞毒性作用物質を結合させたステロイド化合物の誘導体類 | |
| CN117562915A (zh) | 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用 | |
| CN106380400B (zh) | 一种萜品烯醇类化合物及其制备方法和应用 | |
| JPS5810577A (ja) | ２−セノイルメルカプトプロピオニルグリシンのエステル、その製造法およびそれを有効成分とする医薬組成物 | |
| EP4638461A1 (en) | Dual lipid structures | |
| CN116514895A (zh) | 一种环索奈德类似物、制备方法及其应用 | |
| WO2005032540A1 (ja) | Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とする呼吸器疾患治療剤 | |
| CN107868088A (zh) | 苯并二氮杂*类氮氧化物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160226 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20160323 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170317 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170317 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170406 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6126204 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |